|Bid||318.98 x 800|
|Ask||319.15 x 1100|
|Day's Range||311.26 - 319.79|
|52 Week Range||196.68 - 319.79|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||47.46|
|Earnings Date||Aug 04, 2022|
|Forward Dividend & Yield||3.92 (1.28%)|
|Ex-Dividend Date||May 13, 2022|
|1y Target Est||304.28|
The pharma stock Eli Lilly (NYSE: LLY) has surged 13% higher year to date. Let's dive into Eli Lilly's fundamentals and valuation to find out. Eli Lilly reported $7.8 billion in revenue for the first quarter ended March 31, up 14.8% from the year-ago period.
The big shareholder groups in Eli Lilly and Company ( NYSE:LLY ) have power over the company. Institutions will often...
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.